Tempest Therapeutics, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|
| Revenue | $295.0K | $653.0K | $277.0K | $0 | $0 |
| Cost of Revenue | $790.0K | $5.4M | $2.2M | $0 | $0 |
| Gross Profit | $-495.0K | $-4.7M | $-2.0M | $0 | $0 |
| Gross Margin | -167.8% | -727.1% | -711.9% | — | — |
| Operating Expenses | |||||
| Research & Development | $18.3M | $21.6M | $18.4M | $21.8M | $15.8M |
| SG&A Expense | $27.7M | $49.2M | $51.6M | $26.1M | $13.3M |
| Operating Income | $-84.3M | $-81.0M | $-72.0M | $-47.9M | $-29.1M |
| Operating Margin | -28,585.1% | -12,406.1% | -25,992.4% | — | — |
| Interest Expense | $288.0K | — | — | — | — |
| Pretax Income | $-50.9M | $-82.1M | $-73.1M | $-49.5M | $-29.0M |
| Income Tax Expense | $67.0K | $201.0K | $75.0K | $0 | $0 |
| Net Income | $-84.6M | $-82.3M | $-73.2M | $-49.5M | $-29.0M |
| Net Margin | -28,670.5% | -12,597.2% | -26,432.9% | — | — |
| EPS (Basic) | $-13.41 | $-0.11 | $-0.11 | $-0.09 | $-0.08 |
| EPS (Diluted) | $-13.41 | $-0.11 | $-0.11 | $-0.09 | $-0.08 |
| Shares Outstanding (Basic) | 857.4M | 855.4M | 655.1M | 578.0M | 421.0M |
| Shares Outstanding (Diluted) | 857.4M | 855.4M | 655.1M | 578.0M | 421.0M |
| Dividends Per Share | — | — | — | — | — |